Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
December 9, 2020

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

By Matsuoka
Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.

Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle

Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.
Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers

In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.

Gastrointestinal Cancer Antigen (CA 19-9), antigen grade

CA1991-N-10 10 KU
EUR 529

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit

PRB-5069 96 assays
EUR 572

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit

PRB-5069-5 5 x 96 assays
EUR 2283

Cancer Antigen 15-3 MUC 1 Antigen (Human Milk)

VAng-Cr3871-10kU 10 kU
EUR 421
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Paraffin Tissue Section - Human Breast Tumor: Lobular carcinoma

T2235086-3 5 slides
EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody

20-abx148333
  • EUR 425.00
  • EUR 342.00
  • 100 ug
  • 50 ug

Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid)

VAng-Cr3872-10kU 10 kU
EUR 1136
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid.

Cancer Antigen CA 15-3 Protein (Human Fluids)

VAng-Wyb8628-inquire inquire Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Cancer antigen from Human Fluids, 12.240 kU/mL.

Cancer Antigen CA 15-3 Protein (Human Milk)

VAng-Wyb8631-inquire inquire Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL.

Paraffin Tissue Section - Human Brain Tumor: Astrocytoma Grade III

T2235035-3 5 slides
EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Cancer Antigen 15-3 (CA15-3) (human) ELISA Kit

K4804-100 100 assays
EUR 834
Description: Sensitive, Colorimetric Assay

Breast Cancer Exosome

P141-BR - Ask for price

Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium

9-46027 5 x 100 ml Ask for price

Proteinase K, Recombinant, Standard Grade

9250-100
EUR 104

Proteinase K, Recombinant, Standard Grade

9250-10G
EUR 3856

Proteinase K, Recombinant, Standard Grade

9250-1G
EUR 457

Proteinase K, Recombinant, Standard Grade

9250-500
EUR 262

Proteinase K, Recombinant, Standard Grade

9251-100
EUR 1055

Proteinase K, Recombinant, Standard Grade

9251-25
EUR 294

Proteinase K, Recombinant, Standard Grade

9251-5
EUR 120

Fluorescent Exosome Standard (Urine )

ESF-15 100 µg
EUR 1723
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling.

Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells

9-80027 1 x 100 ml Ask for price

Breast Cancer Exosome RNA

P241-BR - Ask for price

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RD-CA15-3-Hu-48Tests 48 Tests
EUR 478

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RD-CA15-3-Hu-96Tests 96 Tests
EUR 662

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

DLR-CA15-3-Hu-48T 48T
EUR 479
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

DLR-CA15-3-Hu-96T 96T
EUR 621
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RDR-CA15-3-Hu-48Tests 48 Tests
EUR 500

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RDR-CA15-3-Hu-96Tests 96 Tests
EUR 692

Polystyrene Particle Size Standard

PPS-3 mL
EUR 127
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone.

Inactivated MuV Grade 3 Antigen

VAng-Lsx0411-inquire inquire Ask for price
Description: MuV grade 3, native protein.

Inactivated CMV Grade 3 Antigen

VAng-Lsx0038-1mg 1 mg
EUR 2086
Description: CMV Grade 3, natural protein.

Inactivated Rotavirus Grade 3 Antigen

VAng-Lsx0469-inquire inquire Ask for price
Description: Rotavirus Grade 3, native virus.

Inactivated RuV Grade 3 Antigen

VAng-Lsx0476-1mL 1 mL
EUR 395
Description: RuV Grade 3, natural protein.

Breast Tumor Lysate

1323 0.1 mg
EUR 254
Description: Breast tumor lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

CA 15-3, Human Breast Adenocarcinoma

P1435-1
EUR 109

CA 15-3, Human Breast Adenocarcinoma

P1435-5
EUR 240

99445-15 DCT 15 X 85MM

99445-15 250/pk
EUR 97
Description: Disposable Culture Tubes; DCT's, CGW

Cancer Antigen 242 Antigen

VAng-Cr3876-10kU 10 kU
EUR 421
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration.

Cancer Antigen 50 Antigen

VAng-Cr3877-50kU 50 kU
EUR 5535
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Breast Cancer Metastasis Suppressor 1

PR27265 2 ug
EUR 191

Inactivated PIV-3 Grade 2 Antigen

VAng-Wyb3637-1mL 1 mL
EUR 1136
Description: Parainfluenza virus type 3 (strain C243) Grade 2, natural antigen

Inactivated HSV-2 Grade 3 Antigen

VAng-Lsx0302-1mg 1 mg
EUR 1489
Description: HSV Type 2 Grade III, native antigen.

Human CA15-3 Antigen Grade Protein

abx060972-250kU 250 kU
EUR 1984

Inactivated HSV-1 Grade 3 Antigen

VAng-Lsx0293-1mg 1 mg
EUR 1489
Description: HSV Type 1 Grade III, native antigen.

Human Breast Tumor lysate

HTL-1323 1 mg
EUR 773

Breast Tumor Kinase Antibody

AF4768 200ul
EUR 376
Description: Breast Tumor Kinase Antibody detects endogenous levels of Breast Tumor Kinase.

Breast Tumor Kinase antibody

70R-31875 100 ug
EUR 327
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tumor Kinase antibody

70R-33385 100 ug
EUR 327
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tissue Lysate (Tumor)

1713-01 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1713-02 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-01 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-02 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-03 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-04 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-05 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-06 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-07 0.1 mg
EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Membrane Tumor Lysate

XBL-10499 0.1 mg
EUR 626.75
Description: Human breast tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human breast tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated breast tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated breast tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Vitamin A Reference Standard (USP grade powder)

51R-U716002 10 pack
EUR 516
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance

CEA Antigen Grade Protein

abx060976-05mg 0.5 mg
EUR 968

CEA Antigen Grade Protein

abx060977-1mg 1 mg
EUR 1692

Prostate Specific Antigen Std Grade Antigen

VAng-Cr3891-1mg 1 mg
EUR 504
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation.

Cancer Antigen 72-4 Antigen

VAng-Cr3878-10kU 10 kU
EUR 421
Description: Cancer Antigen 72-4 Antigen, Host/Source: Metastatic Liver. The purity is ~65% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)

4-RPG768Hu01
  • EUR 501.41
  • EUR 237.00
  • EUR 1605.28
  • EUR 601.76
  • EUR 1103.52
  • EUR 398.00
  • EUR 3863.20
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx129227
  • EUR 425.00
  • EUR 133.00
  • EUR 1205.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

20-abx133658
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

20-abx013807
  • EUR 314.00
  • EUR 98.00
  • EUR 398.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

abx025588-400ul 400 ul
EUR 523

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

abx025588-80l 80 µl
EUR 286

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx171475
  • EUR 857.00
  • EUR 439.00
  • 1 mg
  • 200 ug

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx324781
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Anti-Breast Cancer Resistance Protein antibody

STJ16100903 1 mL
EUR 478

Anti-Breast Cancer Resistance Protein antibody

STJ16100916 1 mL
EUR 478

Breast Cancer Anti-Estrogen Resistance 1

PR27245 2 ug
EUR 191

Breast Cancer Metastasis Suppressor 1 Protein

20-abx263402
  • EUR 1609.00
  • EUR 328.00
  • EUR 230.00
  • 100 ug
  • 10 ug
  • 2 µg

Autobioluminescent Human Breast Cancer Cells (MCF7)

ASE-5903 1 ml
EUR 2075
Description: 6 month

Autobioluminescent Human Breast Cancer Cells (T47D)

ASE-5904 1 ml
EUR 2075
Description: 6 month

Human Breast Cancer Signaling Primer Library

HBRCA-I 1 set
EUR 548

anti-Breast cancer suppressor candidate 1

YF-PA12974 50 ul
EUR 363
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1

YF-PA12975 50 ug
EUR 363
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1

YF-PA24096 50 ul
EUR 334
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

Human Cancer Antigen CA15-3 Protein

abx060965-50kU 50 kU
EUR 2625

Inactivated MuV Grade 3 Antigen (Strain Enders)

VAng-0619Lsx-inquire inquire Ask for price
Description: MuV (Strain Enders) grade 3, native protein. 0.45 mg/mL.

Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues

Z7020007 5 slides
EUR 1381
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

9998 SCREW CAP 415/15

9998-15 288/pk
EUR 198
Description: General Apparatus; Stoppers

Standard grade heat shock BSA powder, pH 7

BAH62-0050 50gm
EUR 257.4

Standard grade heat shock BSA powder, pH 7

BAH62-0100 100gm
EUR 323.7

Standard grade heat shock BSA powder, pH 7

BAH62-0500 500gm
EUR 426.4

Standard grade heat shock BSA powder, pH 7

BAH62-1000 1KG Ask for price

Standard grade heat shock BSA powder, pH 7

BAH62-10000 10KG Ask for price

Standard grade heat shock BSA powder, pH 5.2

BAH63-0050 50gm
EUR 257.4

Standard grade heat shock BSA powder, pH 5.2

BAH63-0100 100gm
EUR 323.7

Standard grade heat shock BSA powder, pH 5.2

BAH63-0500 500gm
EUR 426.4

Standard grade heat shock BSA powder, pH 5.2

BAH63-1000 1KG Ask for price

Standard grade heat shock BSA powder, pH 5.2

BAH63-10000 10KG Ask for price

Cancer Antigen CEA Antigen (Human Fluids)

VAng-Wyb8644-inquire inquire Ask for price
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL.

Cancer Antigen 125 Antigen (Human Adenocarcinoma)

VAng-Cr3868-10kU 10 kU
EUR 421
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography.

Cancer Antigen 125 Antigen (Ascites Fluid)

VAng-Cr3870-10kU 10 kU
EUR 944
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE.

Breast Cancer Estrogen Resistance 3 (BCAR3) Polyclonal Antibody (Human)

4-PAG768Hu01
  • EUR 247.00
  • EUR 2510.00
  • EUR 625.00
  • EUR 310.00
  • EUR 214.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human Breast Cancer Estrogen Resistance 3 (BCAR3)

Cancer of the breast, 75 cases (1.1mm), set 3

BRC1503 1
EUR 250
Description: Breast cancer tissue array, set 3, non-overlapping with BRC1501, BRC1502, BRC1504 to BRC15011,150 cores from normal/benign (5 cases) and cancer (70 cases) tissues in duplicates with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

20-abx134976
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

abx010337-100ug 100 ug
EUR 439

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein

20-abx168253
  • EUR 704.00
  • EUR 286.00
  • EUR 2165.00
  • EUR 829.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

abx432398-200ul 200 ul
EUR 384

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

abx218562-100ug 100 ug
EUR 439

Human Tumor Tissue: Breast cDNA

HT05-090 10 rxn
EUR 415

Breast Tumor Kinase Blocking Peptide

AF4768-BP 1mg
EUR 195

Breast Tumor Kinase antibody (Tyr447)

70R-33384 100 ug
EUR 327
Description: Rabbit polyclonal Breast Tumor Kinase antibody (Tyr447)

ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade

ODNM362-1 1 mg
EUR 651

ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade

ODNM362-5 5 mg
EUR 1991

Human Cancer Antigen CA125 (Ovarian Cancer) Protein

abx061590-100kU 100 kU
EUR 1205

Recombinant CEA Protein (Antigen Grade)

VAng-Wyb8647-inquire inquire Ask for price
Description: Carcinoembryonic Antigen, Antigen Grade, recombinant protein from Cell Culture, 3.71 mg/mL.

Imidazoquinoline (TLR7 Agonist) Antigen Grade

VAdv-Ly0018-25mg 25 mg
EUR 3610
Description: Imidazoquinoline, a TLR7 agonist vaccine adjuvant.

Imidazoquinoline (TLR7 Agonist) Antigen Grade

VAdv-Ly0018-5mg 5 mg
EUR 861
Description: Imidazoquinoline, a TLR7 agonist vaccine adjuvant.

Ck-Mm Antigen Grade Protein

abx060710-1mg 1 mg
EUR 648

Human AFP Antigen Grade Protein

abx060957-1mg 1 mg
EUR 926

Human AFP Antigen Grade Protein

abx060958-1mg 1 mg
EUR 1316

Human AFP Antigen Grade Protein

abx060959-1mg 1 mg
EUR 996

Human CA125 Antigen Grade Protein

abx060960-50kU 50 kU
EUR 801

Inactivated MeV Grade 2 Antigen

VAng-Lsx0384-inquire inquire Ask for price
Description: Measles Grade 2, native virus.

Inactivated MuV Grade 2 Antigen

VAng-Lsx0409-inquire inquire Ask for price
Description: MuV Grade 2, native virus.

Inactivated ADV Grade 2 Antigen

VAng-Lsx0003-1mL 1 mL
EUR 998
Description: ADV Grade 2, natural antigen.

Inactivated CMV Grade 2 Antigen

VAng-Lsx0037-1mg 1 mg
EUR 2027
Description: CMV Grade 2, natural protein.

Inactivated VZV Grade 2 Antigen

VAng-Lsx0555-inquire inquire Ask for price
Description: VZV Grade 2, native virus.

Inactivated RuV Grade 2 Antigen

VAng-Lsx0475-inquire inquire Ask for price
Description: RuV Grade 2, natural protein.

Inactivated RuV Grade 4 Antigen

VAng-Lsx0477-1mg 1 mg
EUR 3080
Description: RuV Grade 4, natural antigen.

Recombinant Human IL-15 Protein

PROTP40933-3 10ug
EUR 317
Description: IL-15 is an immunomodulating cytokine that stimulates the proliferation of T lymphocytes and shares many biological properties with IL-2. IL-15 exerts its biological activites primarily on T cells. It is also essential in the development, survival and activation of NK cells. Increased expression of IL-15 has been implicated with rheumatoid arthritis, inflammatory bowel disease and diseases affiliated with retroviruses HIV and HTLV-I. Human IL-15 is biologically active on mouse cells as measured by the dose-dependent stimulation of the proliferation of mouse CTLL cells. Recombinant human IL-15 is a 12.9 kDa protein consisting of 114 amino acid residues.

Swine IL-15 Recombinant Protein

R00212-3 5ug/vial
EUR 259
Description: Interleukin-15 (IL-15) is a cytokine with structural similarity to IL-2 that is secreted by mononuclear phagocytes following infection by virus(es). This cytokine induces cell proliferation of natural killer cells. Swine IL-15 Recombinant Protein is purified interleukin-15 produced in yeast.

Recombinant (E. coli) Dengue Virus Type 3 E Antigen (DENV-E), antigen grade (>95%, 15 kda, no tag)

RP-1596 50 ug
EUR 408

Paraffin Tissue Section - Human Pancreas Tumor: Islet Cell Tumor

T2235188-3 5 slides
EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Paraffin Tissue Section - Human Breast Tumor: Male Breast Hyperplasia

T2235086-4 5 slides
EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Paraffin Tissue Section - Human Breast Tumor: Medullarycarcinoma of Breast

T2235086-5 5 slides
EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Human Breast cancer metastasis-suppressor 1 (BRMS1)

1-CSB-RP048144h
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Breast cancer metastasis-suppressor 1(BRMS1),partial expressed in E.coli

Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2)

4-RPB364Hu01
  • EUR 530.08
  • EUR 245.00
  • EUR 1712.80
  • EUR 637.60
  • EUR 1175.20
  • EUR 418.00
  • EUR 4132.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Breast Cancer Susceptibility Protein 2 expressed in: E.coli

Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2)

4-RPB364Mu01
  • EUR 530.08
  • EUR 245.00
  • EUR 1712.80
  • EUR 637.60
  • EUR 1175.20
  • EUR 418.00
  • EUR 4132.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Breast Cancer Susceptibility Protein 2 expressed in: E.coli

Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2)

4-RPB364Ra01
  • EUR 544.42
  • EUR 248.00
  • EUR 1766.56
  • EUR 655.52
  • EUR 1211.04
  • EUR 427.00
  • EUR 4266.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Rat Breast Cancer Susceptibility Protein 2 expressed in: E.coli

Recombinant Breast Cancer Susceptibility Protein 1 (BRCA1)

4-RPB376Hu01
  • EUR 601.76
  • EUR 264.00
  • EUR 1981.60
  • EUR 727.20
  • EUR 1354.40
  • EUR 466.00
  • EUR 4804.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Breast Cancer Susceptibility Protein 1 expressed in: E.coli

Recombinant Breast Cancer Susceptibility Protein 1 (BRCA1)

4-RPB376Mu01
  • EUR 521.12
  • EUR 242.00
  • EUR 1679.20
  • EUR 626.40
  • EUR 1152.80
  • EUR 412.00
  • EUR 4048.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Breast Cancer Susceptibility Protein 1 expressed in: E.coli

Recombinant Breast Cancer Susceptibility Protein 1 (BRCA1)

4-RPB376Ra01
  • EUR 571.30
  • EUR 256.00
  • EUR 1867.36
  • EUR 689.12
  • EUR 1278.24
  • EUR 445.00
  • EUR 4518.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Rat Breast Cancer Susceptibility Protein 1 expressed in: E.coli

Anti-Human Breast Cancer Resistance Protein antibody

STJ16100907 1 mL
EUR 478

Anti-Mouse Breast Cancer Resistance Protein antibody

STJ16100917 1 mL
EUR 478
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.